ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Venclexta (venetoclax) is a brand-name oral tablet prescribed for certain types of cancer in adults. As with other drugs, Venclexta can cause side effects, such as nausea, fatigue, or dizziness.

This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to ...